<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pathogenesis of graft-versus-host disease (GVHD)</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pathogenesis of graft-versus-host disease (GVHD)</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Pathogenesis of graft-versus-host disease (GVHD)</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Nelson J Chao, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert Zeiser, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert S Negrin, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alan G Rosmarin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> May 04, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Graft-versus-host disease (GVHD) is the major cause of morbidity and non-relapse mortality in patients after allogeneic hematopoietic cell transplantation (HCT). GVHD refers to multi-organ syndromes of tissue inflammation and/or fibrosis that primarily affect skin, gastrointestinal tract, liver, lungs, and mucosal surfaces. Clinically, GVHD comprises three syndromes, acute GVHD (aGVHD), chronic GVHD (cGVHD), and GVHD overlap syndrome. The various GVHD syndromes are defined by clinical manifestations according to National Institutes of Health consensus criteria [<a href="#rid1">1</a>], rather than the time of onset (ie, before or after day 100 of transplantation, as was used previously). Greater understanding of the underlying pathophysiology is important for more effectively controlling GVHD and improving clinical outcomes with HCT. </p><p>This topic will discuss the pathogenesis of aGVHD and cGVHD.</p><p>Clinical manifestations, diagnosis, grading, treatment, and prevention of aGVHD and cGVHD are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/3549.html" rel="external">"Clinical manifestations, diagnosis, and grading of acute graft-versus-host disease"</a> and  <a class="medical medical_review" href="/z/d/html/3548.html" rel="external">"Clinical manifestations and diagnosis of chronic graft-versus-host disease"</a> and  <a class="medical medical_review" href="/z/d/html/3542.html" rel="external">"Prevention of graft-versus-host disease"</a> and  <a class="medical medical_review" href="/z/d/html/3550.html" rel="external">"Treatment of chronic graft-versus-host disease"</a>.)</p><p>Innate immunity, transplantation immunobiology, and normal B and T lymphocyte development are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/13572.html" rel="external">"An overview of the innate immune system"</a> and  <a class="medical medical_review" href="/z/d/html/7346.html" rel="external">"Transplantation immunobiology"</a> and  <a class="medical medical_review" href="/z/d/html/13933.html" rel="external">"Normal B and T lymphocyte development"</a>.)</p><p class="headingAnchor" id="H910824363"><span class="h1">OVERVIEW OF GVHD</span><span class="headingEndMark"> — </span>GVHD refers to multi-organ syndromes that can develop after allogeneic hematopoietic cell transplantation (HCT). GVHD arises from one of the principal functions of the immune system: distinguishing between self and non-self. GVHD occurs when immune cells transplanted from a non-identical donor (graft) into the recipient (host) recognize the host cells as "foreign," thereby initiating a graft-versus-host reaction [<a href="#rid2">2,3</a>]. Successful transplantation requires that the donor immune system develop tolerance to these alloantigens, while maintaining the ability to recognize and respond to foreign antigens, such as microorganisms or tumor cells.</p><p>GVHD is manifest clinically as three syndromes with different clinical manifestations and temporal courses:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acute GVHD (aGVHD)</strong> – Characterized by a rapid onset and acute disease course</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chronic GVHD (cGVHD)</strong> – Characterized by a chronic disease course that can involve virtually all organs with variable manifestations, including sclerosis </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>GVHD overlap syndrome</strong> – Defined by simultaneous features of both cGVHD and aGVHD</p><p></p><p>Both aGVHD and cGVHD are consequences of the interplay between cellular/immune mediators from the immunological graft with host tissues. Although the two syndromes share some features, they differ with regard to aspects of the underlying pathophysiology, pathology, clinical manifestations, and management. Whereas aGVHD is typically manifest as an inflammatory immune cell infiltrate, including T cells, neutrophils, and monocytes, with tissue destruction, the tissue response in cGVHD is relatively acellular and reveals fibroproliferative findings. Acute GVHD is primarily driven by activation of donor T lymphocytes and release of pro-inflammatory cytokines; by contrast, cGVHD is a more complex and less well-understood syndrome that involves interactions of the innate immune system (macrophages, neutrophils, dendritic cells) with alloreactive and dysregulated B and T cells and non-hematopoietic cells, such as fibroblasts. Further details of the pathophysiologic mechanisms that underlie aGVHD and cGVHD are provided in the sections below. (See <a class="local">'Acute GVHD'</a> below and <a class="local">'Chronic GVHD'</a> below.)</p><p>It is unclear if the GVHD effect can be separated from the graft-versus-tumor effect. (See  <a class="medical medical_review" href="/z/d/html/3546.html" rel="external">"Biology of the graft-versus-tumor effect following hematopoietic cell transplantation", section on 'Possible separation of GVT from GVHD'</a>.)</p><p class="headingAnchor" id="H2416203942"><span class="h1">PATHOPHYSIOLOGY</span><span class="headingEndMark"> — </span>Greater understanding of the pathophysiology is important for development of new and more effective treatments for GVHD. </p><p class="headingAnchor" id="H4238496136"><span class="h2">Acute GVHD</span><span class="headingEndMark"> — </span>Acute GVHD (aGVHD) is primarily manifest as a maculopapular rash, weight loss, diarrhea, and/or hepatitis that typically occurs within the first 100 days after transplantation. Clinical manifestations of aGVHD are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/3549.html" rel="external">"Clinical manifestations, diagnosis, and grading of acute graft-versus-host disease", section on 'Clinical and histological manifestations'</a>.)</p><p>Pathologically, aGVHD is apparent as an inflammatory immune cell infiltrate involving T cells, macrophages, monocytes and neutrophil granulocytes with associated tissue destruction and apoptosis. The transplantation conditioning regimen, innate immune system, and gastrointestinal (GI) microbiome all contribute to the pathophysiology of aGVHD [<a href="#rid4">4,5</a>]: </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Conditioning regimen</strong> – The transplantation conditioning regimen damages the GI epithelium and leads to translocation of bacteria, fungi, and viruses that initiate inflammation mediated by the innate immune system in cooperation with T and B lymphocytes of the adaptive immune system [<a href="#rid6">6,7</a>]. Macrophages, neutrophils, and dendritic cells mediate this response through Toll-like receptors (TLR) and through nucleotide-binding and oligomerization domain (NOD)-like receptors (NLRs), which are involved in pathogen recognition via patterns of nucleic acids or sugars [<a href="#rid8">8-11</a>]. Non-pathogen associated molecules such as uric acid, adenosine triphosphate, or IL-33 (so-called damage associated molecular patterns [DAMPs]) also promote aGVHD [<a href="#rid12">12,13</a>]. Cellular components of the innate immune system and TLRs are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/13572.html" rel="external">"An overview of the innate immune system"</a> and  <a class="medical medical_review" href="/z/d/html/3985.html" rel="external">"Toll-like receptors: Roles in disease and therapy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Inflammatory milieu</strong> – A pro-inflammatory milieu activates antigen presenting cells (APC) that prime naïve T cells to Th1 and Th17 differentiation, expand T effector cells, and target host tissues. Scavenger macrophages, plasmacytoid and myeloid dendritic cells, B cells, and neutrophils produce cytokines that enhance antigen presentation and drive differentiation to the Th1 and Th17 effector lineages [<a href="#rid6">6</a>]. Signaling through Janus kinase (JAK)1 and JAK2 and signal transducers and activators of transcription (STAT) contributes to inflammation and tissue damage by neutrophils, dendritic cells, and inflammatory cytokines [<a href="#rid14">14-18</a>]. TLR pathway activation induces transcriptional activation of interferon (IFN) alpha (IFNa) through IFN response factors (IRF 3, IRF 7) and induces tumor necrosis factor (TNF) and interleukin (IL)-6 through nuclear factor kappa B (NFkB) [<a href="#rid19">19-21</a>]. IFNa can drive Th1 commitment and result in IFN gamma (IFNg) production and, together, IFNa and IFNg induce chemokines (eg, CXCL9, CXCL10, CXCL11) that recruit Th1 cells to sites of inflammation and enhance processing and presentation of host antigens [<a href="#rid6">6,22</a>]. Inflammasome complexes catalyze production of IL-1b and IL-18 which, together with IL-6, induce differentiation of Th17 cells, regulate antigen presentation and migration of dendritic cells and lymphocytes, and result in loss of myeloid-derived suppressor cell function [<a href="#rid23">23,24</a>]. Human beta-defensin 2 (hBD-2), an endogenous epithelial cell-derived host-defense peptide, was shown to reduce inflammation in mice developing aGVHD [<a href="#rid25">25</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tissue regeneration</strong> – Acute GVHD also affects enterocytes, intestinal stem cells (ISC), and Paneth cells and dysregulates tissue-regenerative mechanisms such as intestinal stem cell (ISC) and Paneth cell repair; these effects may enable therapeutic strategies to enhance intestinal cell repair (eg, treatment with IL-22, R-spondin, keratinocyte growth factor, and Glucagon-like peptide 2) [<a href="#rid26">26-29</a>].</p><p></p><p>Experimental models and clinical experience confirm the importance of innate immunity and TLRs in aGVHD. Deletion or inhibition of TLR or NOD-like receptor pathways significantly reduce aGVHD [<a href="#rid30">30-33</a>]. Furthermore, polymorphisms of proteins that mediate innate immunity are associated with clinical outcomes in HCT [<a href="#rid34">34</a>]. As an example, NOD2/CARD15 is an intracellular sensor of muramyl dipeptide (a component of the bacterial cell wall) that is expressed by intestinal epithelial cells and cells of monocyte/macrophage lineage and mediates activation of NFkB. In a study of 169 consecutive patients receiving transplants from related or unrelated donors, polymorphisms of <em>NOD2/CARD15 </em>were found in 21 percent of recipients and 14 percent of donors [<a href="#rid34">34</a>]. The cumulative incidence of one-year transplant-related mortality rose from 20 percent in donor/recipient pairs without single nucleotide polymorphisms, to 49 percent in pairs with recipient mutations, 59 percent in pairs with donor mutations, and 83 percent in 12 pairs with mutated alleles in both donor and recipient. </p><p>Observational studies suggest that the diversity and composition of the GI microbiome (ie, intestinal bacteria) plays a role in the development of GVHD involving the lower GI tract, as discussed in more detail separately. </p><p class="headingAnchor" id="H820470043"><span class="h2">Chronic GVHD</span><span class="headingEndMark"> — </span>Chronic GVHD (cGVHD) is manifest as fibrosis and chronic inflammation of skin, lungs, GI tract, and soft tissues that generally presents ≥100 days after transplantation. Clinical aspects of cGVHD are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/3548.html" rel="external">"Clinical manifestations and diagnosis of chronic graft-versus-host disease", section on 'Clinical manifestations'</a>.)</p><p>Pathologically, tissues affected by cGVHD are relatively acellular and fibroproliferative. Development of cGVHD is a complex, multi-phase process that involves various cell lineages and types of injury [<a href="#rid6">6,19,35</a>]. In cGVHD, early inflammation results from the conditioning regimen and activation of donor T cells. Injury of vascular endothelial cells (EC) facilitates migration of donor immune cells into target organs. Donor-derived effector T lymphocytes, B lymphocytes, and APCs mount an immune response against host tissues. Immune tolerance is affected by depletion of regulatory T cells (Treg) and their functional suppression by calcineurin inhibitors [<a href="#rid36">36</a>], along with thymic injury/dysfunction [<a href="#rid37">37</a>]. Aberrant repair mechanisms foster activation of fibroblasts, collagen deposition, and fibrosis that lead to irreversible end-organ injury and dysfunction.</p><p>Experimental studies support a three-phase model of cGVHD [<a href="#rid6">6</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Early inflammation and tissue injury</strong> – Early inflammation and tissue injury in cGVHD is initiated and sustained by the innate immune system. The cellular components (ie, macrophages, neutrophils, dendritic cells, and B cells), signaling mechanisms (eg, TLR and NOD-like pathways), and mediators (eg, cytokines) of cGVHD resemble the mechanisms that underlie aGVHD [<a href="#rid6">6</a>], as described above. (See <a class="local">'Acute GVHD'</a> above.)</p><p></p><p class="bulletIndent1">Activation and injury of ECs contribute to early inflammation in cGVHD [<a href="#rid6">6</a>]. ECs function as a barrier between donor and recipient tissues and they are the first host cells encountered by the transplanted donor immune system. EC injury and early inflammation may be caused by irradiation, lipopolysaccharide, TNFa, and cytotoxic lymphocytes. </p><p></p><p class="bulletIndent1">Mature donor T cells infused with the transplanted host graft also contribute to inflammation. Depletion of T cells in vivo or short courses of <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a> reduce the incidence and severity of cGVHD, which supports this observation [<a href="#rid6">6</a>]. Activation and clonal expansion of donor T cells into Th2 and Th17 functional subsets produces inflammatory cytokines and cytolytic enzymes that contribute to the early inflammation of cGVHD. Mobilization of peripheral blood stem cells with granulocyte colony-stimulating factor (G-CSF) also promotes Th17 differentiation [<a href="#rid38">38</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chronic inflammation and tissue injury</strong> – Donor- and/or host-derived immune regulatory responses are not sufficient to control the early inflammation, which results in chronic inflammation and dysregulated immunity [<a href="#rid6">6</a>]. Tregs are important for immune homeostasis and immune tolerance, and dysregulated Tregs contribute to sustained inflammation in cGVHD, although the underlying mechanisms are poorly defined [<a href="#rid6">6,39,40</a>]. Effects of early inflammation on the thymus may also contribute to a lack of immune tolerance and sustained inflammation in cGVHD [<a href="#rid41">41</a>]. Disordered immune suppression by type 1 regulatory T cells (Tr1), myeloid-derived suppressor cells, and other cell types also contribute to persistent inflammation [<a href="#rid42">42-44</a>].</p><p></p><p class="bulletIndent1">Diminished immune regulatory functions of B cells and natural killer (NK) cells also contribute to chronic inflammation. Detection of autoantibodies against minor histocompatibility antigens, antinuclear antibodies (ANA), anti-double-stranded DNA indicate a loss of B cell tolerance [<a href="#rid45">45</a>]. NK cells are cytotoxic lymphocytes that express killer-cell immunoglobulin-like receptors (KIR), which can detect major histocompatibility complex (MHC) on the cell surface, trigger cytokine release, and cause lysis or apoptosis of target cells. KIR haplotypes can be activating or inhibitory. (See  <a class="medical medical_review" href="/z/d/html/13572.html" rel="external">"An overview of the innate immune system", section on 'Natural killer cells'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Aberrant tissue repair and fibrosis</strong> – Dysregulated immunity and aberrant tissue repair contribute to scarring and fibrosis in cGVHD [<a href="#rid6">6</a>]. Early EC damage activates coagulation pathways that release chemotactic factors, and macrophages are a source of transforming growth factor (TGF) beta (TGFb), TNFa, IL-1b, platelet-derived growth factor (PDGF), and matric metalloproteinases, with an ensuing cascade of fibrosis [<a href="#rid46">46</a>]. IL-22 may also contribute to cutaneous manifestations of cGVHD [<a href="#rid47">47</a>]. Fibroblasts contribute to extracellular matrix production and collagen deposition.</p><p></p><p class="bulletIndent1">Adaptive immunity also contributes to tissue injury and scarring. Activated Th2 and Th17 T cells promote fibrosis by secretion of IL-13 and IL-17, respectively [<a href="#rid6">6</a>]. B cell activation contributes auto- and allo-antibody production which, in concert with colony-stimulating factor 1 (CSF-1), further activate monocytes and macrophages to release TGFb, which activates myofibroblasts and collagen production leading to further tissue scarring and fibrosis [<a href="#rid48">48</a>].</p><p></p><p class="headingAnchor" id="H2567827988"><span class="h1">CONTRIBUTING FACTORS</span></p><p class="headingAnchor" id="H953761819"><span class="h2">Histocompatibility</span><span class="headingEndMark"> — </span>GVHD arises when immune cells transplanted from a non-identical graft recognize cells in the host as foreign. The major histocompatibility complex (MHC) provides the crucial surface upon which foreign antigens are displayed for immune recognition by T lymphocytes. Minor antigens also contribute to tissue histocompatibility. The MHC and mechanisms of allorecognition are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/7346.html" rel="external">"Transplantation immunobiology"</a>.)</p><p class="headingAnchor" id="H2926750498"><span class="h2">MHC/HLA antigens</span><span class="headingEndMark"> — </span>In humans, MHC molecules are called human leukocyte antigens (HLA). HLA is highly polymorphic from individual to individual and segregates in families in a Mendelian codominant fashion. (See  <a class="medical medical_review" href="/z/d/html/7346.html" rel="external">"Transplantation immunobiology", section on 'Major histocompatibility complex structure and function'</a>.)</p><p>In allogeneic hematopoietic cell transplantation (HCT), the principal antigenic targets of the T cells of the graft are host MHC molecules. The genes of the HLA locus encode two distinct classes of cell surface molecules, class I and class II. There are three different class I (HLA-A, -B, -C) and class II (HLA-DQ, -DR, -DP) antigens. HLA-A, -B and -DR antigens appear to be the most important loci for determining whether transplanted cells initiate a graft-versus-host reaction [<a href="#rid49">49</a>]. Class I molecules are expressed on the surfaces of virtually all nucleated cells at varying densities, while class II molecules are more restricted to cells of the immune system, primarily B lymphocytes and monocytes. However, cytokines secreted by lymphocytes and monocytes during immune activation may cause dramatic increases in class II HLA antigen expression, even on cell types that normally have little or no surface expression. (See  <a class="medical medical_review" href="/z/d/html/3987.html" rel="external">"Human leukocyte antigens (HLA): A roadmap"</a>.)</p><p>Antigen-presenting cells, such as macrophages, present a complex of an MHC molecule bearing a small peptide fragment to a lymphocyte, which expresses a single T cell receptor (TCR). Class II molecules display antigenic peptide fragments to CD4-positive inducer (helper) T cells. Class I molecules function at the effector phase of immunity by presenting antigens to CD8-positive T cells, which generally have cytotoxic/suppressor function. (See  <a class="medical medical_review" href="/z/d/html/7346.html" rel="external">"Transplantation immunobiology"</a>.)</p><p>The role of MHC/HLA in selection of a donor for HCT is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/3535.html" rel="external">"Donor selection for hematopoietic cell transplantation"</a>.)</p><p class="headingAnchor" id="H2075006311"><span class="h2">Minor histocompatibility antigens</span><span class="headingEndMark"> — </span>GVHD can develop even with grafts that are fully matched at the MHC/HLA loci due to mismatching of other antigens, termed minor histocompatibility antigens (miH). </p><p>Minor antigens (miH) are presented in the context of MHC. Because the manner in which a particular protein is processed is dependent upon genes outside of the MHC, two siblings, despite having identical MHC molecules, will have different peptides in the MHC groove [<a href="#rid50">50,51</a>]. MHC class I-related chain A (MICA) and killer-cell immunoglobulin-like receptor (KIR) are examples of miH that can cause rejection. Other specific proteins that account for miH in humans are poorly defined. (See  <a class="medical medical_review" href="/z/d/html/7346.html" rel="external">"Transplantation immunobiology", section on 'Minor transplantation antigens'</a>.)</p><p class="headingAnchor" id="H2052954887"><span class="h2">Histocompatibility antigen matching</span><span class="headingEndMark"> — </span>HLA can be matched serologically or using genetic-based testing, as discussed separately. (See  <a class="medical medical_review" href="/z/d/html/3987.html" rel="external">"Human leukocyte antigens (HLA): A roadmap"</a>.)</p><p class="headingAnchor" id="H3001684882"><span class="h2">Tissue microenvironment</span><span class="headingEndMark"> — </span>Cells, cytokines, and signaling pathways of the tissue microenvironment contribute to GVHD and the graft-versus-leukemia (GVL) effect. </p><p>As an example, Notch signaling, which orchestrates cell fate and differentiation, is critical in both acute and chronic GVHD. Notch inhibition results in blockade of multiple cytokines, expansion of T regs and decrease in pathogenic T cells without decreasing GVL [<a href="#rid52">52</a>]. Similarly, T follicular helper cells in germinal centers of secondary lymphoid organs contribute to development of GVHD [<a href="#rid53">53</a>].</p><p class="headingAnchor" id="H3785976920"><span class="h2">Clinical factors</span><span class="headingEndMark"> — </span>A number of clinical variables are associated with the development of GVHD and may influence the underlying pathophysiology [<a href="#rid6">6</a>]. Factors that relate to clinical features of the recipient and the donor are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/3549.html" rel="external">"Clinical manifestations, diagnosis, and grading of acute graft-versus-host disease", section on 'Risk factors'</a> and  <a class="medical medical_review" href="/z/d/html/3535.html" rel="external">"Donor selection for hematopoietic cell transplantation"</a>.)</p><p>Clinical factors that contribute to GVHD include:</p><p class="bulletIndent1"><span class="glyph">●</span>Donor type (ie, matched related, matched unrelated, haploidentical)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Source (peripheral blood, bone marrow, umbilical cord)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Sex-mismatch</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Age of donor and recipient </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Conditioning regimen intensity</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Underlying malignancy (eg, myelodysplastic syndrome, acute or chronic myeloid or lymphoid leukemia)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>T cell depletion in vivo (eg, anti-thymocyte globulins, <a class="drug drug_general" data-topicid="8725" href="/z/d/drug information/8725.html" rel="external">alemtuzumab</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Post-transplantation <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a></p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Infection history (eg, CMV, EBV)</p><p></p><p>The roles of these factors in selection of a HCT donor are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/3535.html" rel="external">"Donor selection for hematopoietic cell transplantation", section on 'Effect of donor characteristics'</a>.)</p><p class="headingAnchor" id="H1841125358"><span class="h2">Microbiome</span><span class="headingEndMark"> — </span>The composition of gastrointestinal microbiota has been associated with outcomes in patients who undergo allogeneic HCT. However, it is not clear that this is a causal relationship or if it is possible to manipulate the intestinal microbiome to influence outcomes.</p><p>An increase of potentially pathogenic bacteria and loss of diversity in the number of bacterial taxa is commonly found in patients undergoing allogeneic HCT [<a href="#rid54">54-57</a>]. A large international study reported that higher diversity of intestinal microbiota was associated with lower mortality, lower rates of transplant-related death, and fewer deaths attributable to GVHD [<a href="#rid58">58</a>]. The study profiled 8767 fecal samples from 1362 patients at four institutions and used 16S ribosomal RNA sequence to stratify patients into higher-diversity (HD) and lower-diversity (LD) groups. In a preliminary study at one of the institutions, compared with LD patients, patients with HD had a hazard ratio (HR) for death of 0.71 (95% CI 0.55-0.92); analysis from three other institutions reported the HR for death was 0.49 (95% CI 0.27-0.90). Samples obtained before transplantation already showed evidence of microbiome disruption, and lower diversity before transplantation was also associated with poor survival. Single-institution studies have reported similar associations between diversity of intestinal microbiota and transplantation outcomes [<a href="#rid59">59-61</a>].</p><p class="headingAnchor" id="H25784855"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Description</strong> – Graft-versus-host disease (GVHD) is the major source of non-relapse morbidity and mortality in patients who undergo allogeneic hematopoietic cell transplantation (HCT). GVHD refers to multi-organ syndromes of tissue inflammation and/or fibrosis that primarily affect skin, gastrointestinal tract, liver, lungs, and mucosal surfaces. Greater understanding of the pathophysiology of GVHD is important for development of new and more effective treatments. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Overview</strong> – GVHD arises when immune cells transplanted from a non-identical donor (graft) into the recipient (host) recognize the host cells as "foreign," thereby initiating a graft-versus-host reaction. GVHD is manifest clinically as three syndromes that are generally defined by their clinical manifestation (see <a class="local">'Overview of GVHD'</a> above):</p><p></p><p class="bulletIndent1">GVHD comprises three syndromes:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Acute GVHD (aGVHD)</strong> – Characterized by a rapid onset and acute disease course</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Chronic GVHD (cGVHD)</strong> – Characterized by a chronic disease course that can involve virtually all organs with variable manifestations, including sclerosis </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>GVHD overlap syndrome</strong> – Defined by simultaneous features of both cGVHD and aGVHD</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acute GVHD</strong> – Pathologically, aGVHD is manifest as an inflammatory immune cell infiltrate involving T cells, macrophages, monocytes and neutrophil granulocytes with associated tissue destruction and apoptosis. The transplantation conditioning regimen, innate immune system, impaired tissue repair mechanisms, and gastrointestinal microbiome all contribute to the pathophysiology of aGVHD. (See <a class="local">'Acute GVHD'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chronic GVHD</strong> – Tissues affected by cGVHD are relatively acellular and fibroproliferative. The pathogenesis of cGVHD is a complex process that involves early inflammation and tissue injury, chronic inflammation and dysregulated immunity, and aberrant tissue repair and fibrosis. Description of the cellular components and signaling pathways the mediate cGVHD are discussed above. (See <a class="local">'Chronic GVHD'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Histocompatibility antigens </strong>– Proteins of the major histocompatibility complex (MHC) are the principal antigenic determinants of graft rejection; in humans, MHC proteins are called human leukocyte antigens (HLA). Genes of the HLA locus encode two distinct classes of cell surface molecules, class I and class II, which are expressed by different cell types, are highly polymorphic from individual to individual, and provide the surface upon which foreign antigens are displayed for immune recognition by T lymphocytes. (See <a class="local">'MHC/HLA antigens'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Vigorito AC, Campregher PV, Storer BE, et al. Evaluation of NIH consensus criteria for classification of late acute and chronic GVHD. Blood 2009; 114:702.</a></li><li><a class="nounderline abstract_t">Zeiser R, Blazar BR. Acute Graft-versus-Host Disease - Biologic Process, Prevention, and Therapy. N Engl J Med 2017; 377:2167.</a></li><li><a class="nounderline abstract_t">Ferrara JL, Levine JE, Reddy P, Holler E. Graft-versus-host disease. Lancet 2009; 373:1550.</a></li><li><a class="nounderline abstract_t">Jenq RR, Ubeda C, Taur Y, et al. Regulation of intestinal inflammation by microbiota following allogeneic bone marrow transplantation. J Exp Med 2012; 209:903.</a></li><li><a class="nounderline abstract_t">Mathewson ND, Jenq R, Mathew AV, et al. Gut microbiome-derived metabolites modulate intestinal epithelial cell damage and mitigate graft-versus-host disease. Nat Immunol 2016; 17:505.</a></li><li><a class="nounderline abstract_t">Cooke KR, Luznik L, Sarantopoulos S, et al. The Biology of Chronic Graft-versus-Host Disease: A Task Force Report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease. Biol Blood Marrow Transplant 2017; 23:211.</a></li><li><a class="nounderline abstract_t">Legoff J, Resche-Rigon M, Bouquet J, et al. The eukaryotic gut virome in hematopoietic stem cell transplantation: new clues in enteric graft-versus-host disease. Nat Med 2017; 23:1080.</a></li><li><a class="nounderline abstract_t">Heidegger S, van den Brink MR, Haas T, Poeck H. The role of pattern-recognition receptors in graft-versus-host disease and graft-versus-leukemia after allogeneic stem cell transplantation. Front Immunol 2014; 5:337.</a></li><li><a class="nounderline abstract_t">Ramadan A, Paczesny S. Various forms of tissue damage and danger signals following hematopoietic stem-cell transplantation. Front Immunol 2015; 6:14.</a></li><li><a class="nounderline abstract_t">Zeiser R, Penack O, Holler E, Idzko M. Danger signals activating innate immunity in graft-versus-host disease. J Mol Med (Berl) 2011; 89:833.</a></li><li><a class="nounderline abstract_t">Blazar BR, Murphy WJ, Abedi M. Advances in graft-versus-host disease biology and therapy. Nat Rev Immunol 2012; 12:443.</a></li><li><a class="nounderline abstract_t">Wilhelm K, Ganesan J, Müller T, et al. Graft-versus-host disease is enhanced by extracellular ATP activating P2X7R. Nat Med 2010; 16:1434.</a></li><li><a class="nounderline abstract_t">Reichenbach DK, Schwarze V, Matta BM, et al. The IL-33/ST2 axis augments effector T-cell responses during acute GVHD. Blood 2015; 125:3183.</a></li><li><a class="nounderline abstract_t">Spoerl S, Mathew NR, Bscheider M, et al. Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease. Blood 2014; 123:3832.</a></li><li><a class="nounderline abstract_t">Choi J, Cooper ML, Alahmari B, et al. Pharmacologic blockade of JAK1/JAK2 reduces GvHD and preserves the graft-versus-leukemia effect. PLoS One 2014; 9:e109799.</a></li><li><a class="nounderline abstract_t">Carniti C, Gimondi S, Vendramin A, et al. Pharmacologic Inhibition of JAK1/JAK2 Signaling Reduces Experimental Murine Acute GVHD While Preserving GVT Effects. Clin Cancer Res 2015; 21:3740.</a></li><li><a class="nounderline abstract_t">Stickel N, Hanke K, Marschner D, et al. MicroRNA-146a reduces MHC-II expression via targeting JAK/STAT signaling in dendritic cells after stem cell transplantation. Leukemia 2017; 31:2732.</a></li><li><a class="nounderline abstract_t">Hülsdünker J, Ottmüller KJ, Neeff HP, et al. Neutrophils provide cellular communication between ileum and mesenteric lymph nodes at graft-versus-host disease onset. Blood 2018; 131:1858.</a></li><li><a class="nounderline abstract_t">MacDonald KP, Hill GR, Blazar BR. Chronic graft-versus-host disease: biological insights from preclinical and clinical studies. Blood 2017; 129:13.</a></li><li><a class="nounderline abstract_t">Coghill JM, Sarantopoulos S, Moran TP, et al. Effector CD4+ T cells, the cytokines they generate, and GVHD: something old and something new. Blood 2011; 117:3268.</a></li><li><a class="nounderline abstract_t">Shlomchik WD, Lee SJ, Couriel D, Pavletic SZ. Transplantation's greatest challenges: advances in chronic graft-versus-host disease. Biol Blood Marrow Transplant 2007; 13:2.</a></li><li><a class="nounderline abstract_t">Amarnath S, Flomerfelt FA, Costanzo CM, et al. Rapamycin generates anti-apoptotic human Th1/Tc1 cells via autophagy for induction of xenogeneic GVHD. Autophagy 2010; 6:523.</a></li><li><a class="nounderline abstract_t">Koehn BH, Apostolova P, Haverkamp JM, et al. GVHD-associated, inflammasome-mediated loss of function in adoptively transferred myeloid-derived suppressor cells. Blood 2015; 126:1621.</a></li><li><a class="nounderline abstract_t">Koehn BH, Saha A, McDonald-Hyman C, et al. Danger-associated extracellular ATP counters MDSC therapeutic efficacy in acute GVHD. Blood 2019; 134:1670.</a></li><li><a class="nounderline abstract_t">Rückert T, Andrieux G, Boerries M, et al. Human β-defensin 2 ameliorates acute GVHD by limiting ileal neutrophil infiltration and restraining T cell receptor signaling. Sci Transl Med 2022; 14:eabp9675.</a></li><li><a class="nounderline abstract_t">Lindemans CA, Calafiore M, Mertelsmann AM, et al. Interleukin-22 promotes intestinal-stem-cell-mediated epithelial regeneration. Nature 2015; 528:560.</a></li><li><a class="nounderline abstract_t">Takashima S, Kadowaki M, Aoyama K, et al. The Wnt agonist R-spondin1 regulates systemic graft-versus-host disease by protecting intestinal stem cells. J Exp Med 2011; 208:285.</a></li><li><a class="nounderline abstract_t">Krijanovski OI, Hill GR, Cooke KR, et al. Keratinocyte growth factor separates graft-versus-leukemia effects from graft-versus-host disease. Blood 1999; 94:825.</a></li><li><a class="nounderline abstract_t">Norona J, Apostolova P, Schmidt D, et al. Glucagon-like peptide 2 for intestinal stem cell and Paneth cell repair during graft-versus-host disease in mice and humans. Blood 2020; 136:1442.</a></li><li><a class="nounderline abstract_t">Cooke KR, Gerbitz A, Crawford JM, et al. LPS antagonism reduces graft-versus-host disease and preserves graft-versus-leukemia activity after experimental bone marrow transplantation. J Clin Invest 2001; 107:1581.</a></li><li><a class="nounderline abstract_t">Zhao Y, Liu Q, Yang L, et al. TLR4 inactivation protects from graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Cell Mol Immunol 2013; 10:165.</a></li><li><a class="nounderline abstract_t">Hill GR, Teshima T, Gerbitz A, et al. Differential roles of IL-1 and TNF-alpha on graft-versus-host disease and graft versus leukemia. J Clin Invest 1999; 104:459.</a></li><li><a class="nounderline abstract_t">Jankovic D, Ganesan J, Bscheider M, et al. The Nlrp3 inflammasome regulates acute graft-versus-host disease. J Exp Med 2013; 210:1899.</a></li><li><a class="nounderline abstract_t">Holler E, Rogler G, Herfarth H, et al. Both donor and recipient NOD2/CARD15 mutations associate with transplant-related mortality and GvHD following allogeneic stem cell transplantation. Blood 2004; 104:889.</a></li><li><a class="nounderline abstract_t">MacDonald KP, Blazar BR, Hill GR. Cytokine mediators of chronic graft-versus-host disease. J Clin Invest 2017; 127:2452.</a></li><li><a class="nounderline abstract_t">Zeiser R, Nguyen VH, Beilhack A, et al. Inhibition of CD4+CD25+ regulatory T-cell function by calcineurin-dependent interleukin-2 production. Blood 2006; 108:390.</a></li><li><a class="nounderline abstract_t">Wu T, Young JS, Johnston H, et al. Thymic damage, impaired negative selection, and development of chronic graft-versus-host disease caused by donor CD4+ and CD8+ T cells. J Immunol 2013; 191:488.</a></li><li><a class="nounderline abstract_t">Hill GR, Olver SD, Kuns RD, et al. Stem cell mobilization with G-CSF induces type 17 differentiation and promotes scleroderma. Blood 2010; 116:819.</a></li><li><a class="nounderline abstract_t">Sakaguchi S, Miyara M, Costantino CM, Hafler DA. FOXP3+ regulatory T cells in the human immune system. Nat Rev Immunol 2010; 10:490.</a></li><li><a class="nounderline abstract_t">Matsuoka K, Kim HT, McDonough S, et al. Altered regulatory T cell homeostasis in patients with CD4+ lymphopenia following allogeneic hematopoietic stem cell transplantation. J Clin Invest 2010; 120:1479.</a></li><li><a class="nounderline abstract_t">Sakoda Y, Hashimoto D, Asakura S, et al. Donor-derived thymic-dependent T cells cause chronic graft-versus-host disease. Blood 2007; 109:1756.</a></li><li><a class="nounderline abstract_t">Zhang P, Lee JS, Gartlan KH, et al. Eomesodermin promotes the development of type 1 regulatory T (TR1) cells. Sci Immunol 2017; 2.</a></li><li><a class="nounderline abstract_t">Highfill SL, Rodriguez PC, Zhou Q, et al. Bone marrow myeloid-derived suppressor cells (MDSCs) inhibit graft-versus-host disease (GVHD) via an arginase-1-dependent mechanism that is up-regulated by interleukin-13. Blood 2010; 116:5738.</a></li><li><a class="nounderline abstract_t">Blazar BR, MacDonald KPA, Hill GR. Immune regulatory cell infusion for graft-versus-host disease prevention and therapy. Blood 2018; 131:2651.</a></li><li><a class="nounderline abstract_t">Patriarca F, Skert C, Sperotto A, et al. The development of autoantibodies after allogeneic stem cell transplantation is related with chronic graft-vs-host disease and immune recovery. Exp Hematol 2006; 34:389.</a></li><li><a class="nounderline abstract_t">Wynn TA, Ramalingam TR. Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nat Med 2012; 18:1028.</a></li><li><a class="nounderline abstract_t">Gartlan KH, Bommiasamy H, Paz K, et al. A critical role for donor-derived IL-22 in cutaneous chronic GVHD. Am J Transplant 2018; 18:810.</a></li><li><a class="nounderline abstract_t">Alexander KA, Flynn R, Lineburg KE, et al. CSF-1-dependant donor-derived macrophages mediate chronic graft-versus-host disease. J Clin Invest 2014; 124:4266.</a></li><li><a class="nounderline abstract_t">Prasad VK, Kernan NA, Heller G, et al. DNA typing for HLA-A and HLA-B identifies disparities between patients and unrelated donors matched by HLA-A and HLA-B serology and HLA-DRB1. Blood 1999; 93:399.</a></li><li><a class="nounderline abstract_t">Schlegel PG, Aharoni R, Smilek DE, et al. Prevention of graft-versus-host disease by peptides binding to class II major histocompatibility complex molecules. Blood 1994; 84:2802.</a></li><li><a class="nounderline abstract_t">Jameson BA, McDonnell JM, Marini JC, Korngold R. A rationally designed CD4 analogue inhibits experimental allergic encephalomyelitis. Nature 1994; 368:744.</a></li><li><a class="nounderline abstract_t">Brandstadter JD, Maillard I. Notch signalling in T cell homeostasis and differentiation. Open Biol 2019; 9:190187.</a></li><li><a class="nounderline abstract_t">Socié G, Kean LS, Zeiser R, Blazar BR. Insights from integrating clinical and preclinical studies advance understanding of graft-versus-host disease. J Clin Invest 2021; 131.</a></li><li><a class="nounderline abstract_t">Holler E, Butzhammer P, Schmid K, et al. Metagenomic analysis of the stool microbiome in patients receiving allogeneic stem cell transplantation: loss of diversity is associated with use of systemic antibiotics and more pronounced in gastrointestinal graft-versus-host disease. Biol Blood Marrow Transplant 2014; 20:640.</a></li><li><a class="nounderline abstract_t">Taur Y, Xavier JB, Lipuma L, et al. Intestinal domination and the risk of bacteremia in patients undergoing allogeneic hematopoietic stem cell transplantation. Clin Infect Dis 2012; 55:905.</a></li><li><a class="nounderline abstract_t">Golob JL, Pergam SA, Srinivasan S, et al. Stool Microbiota at Neutrophil Recovery Is Predictive for Severe Acute Graft vs Host Disease After Hematopoietic Cell Transplantation. Clin Infect Dis 2017; 65:1984.</a></li><li><a class="nounderline abstract_t">Stoma I, Littmann ER, Peled JU, et al. Compositional Flux Within the Intestinal Microbiota and Risk for Bloodstream Infection With Gram-negative Bacteria. Clin Infect Dis 2021; 73:e4627.</a></li><li><a class="nounderline abstract_t">Peled JU, Gomes ALC, Devlin SM, et al. Microbiota as Predictor of Mortality in Allogeneic Hematopoietic-Cell Transplantation. N Engl J Med 2020; 382:822.</a></li><li><a class="nounderline abstract_t">Taur Y, Jenq RR, Perales MA, et al. The effects of intestinal tract bacterial diversity on mortality following allogeneic hematopoietic stem cell transplantation. Blood 2014; 124:1174.</a></li><li><a class="nounderline abstract_t">Peled JU, Devlin SM, Staffas A, et al. Intestinal Microbiota and Relapse After Hematopoietic-Cell Transplantation. J Clin Oncol 2017; 35:1650.</a></li><li><a class="nounderline abstract_t">Haak BW, Littmann ER, Chaubard JL, et al. Impact of gut colonization with butyrate-producing microbiota on respiratory viral infection following allo-HCT. Blood 2018; 131:2978.</a></li></ol></div><div id="topicVersionRevision">Topic 3545 Version 30.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19470693" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Evaluation of NIH consensus criteria for classification of late acute and chronic GVHD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29171820" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Acute Graft-versus-Host Disease - Biologic Process, Prevention, and Therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19282026" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Graft-versus-host disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22547653" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Regulation of intestinal inflammation by microbiota following allogeneic bone marrow transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26998764" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Gut microbiome-derived metabolites modulate intestinal epithelial cell damage and mitigate graft-versus-host disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27713092" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : The Biology of Chronic Graft-versus-Host Disease: A Task Force Report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28759053" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : The eukaryotic gut virome in hematopoietic stem cell transplantation: new clues in enteric graft-versus-host disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25101080" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : The role of pattern-recognition receptors in graft-versus-host disease and graft-versus-leukemia after allogeneic stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25674088" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Various forms of tissue damage and danger signals following hematopoietic stem-cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21573893" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Danger signals activating innate immunity in graft-versus-host disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22576252" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Advances in graft-versus-host disease biology and therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21102458" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Graft-versus-host disease is enhanced by extracellular ATP activating P2X7R.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25814531" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : The IL-33/ST2 axis augments effector T-cell responses during acute GVHD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24711661" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25289677" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Pharmacologic blockade of JAK1/JAK2 reduces GvHD and preserves the graft-versus-leukemia effect.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25977345" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Pharmacologic Inhibition of JAK1/JAK2 Signaling Reduces Experimental Murine Acute GVHD While Preserving GVT Effects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28484267" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : MicroRNA-146a reduces MHC-II expression via targeting JAK/STAT signaling in dendritic cells after stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29463561" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Neutrophils provide cellular communication between ileum and mesenteric lymph nodes at graft-versus-host disease onset.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27821504" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Chronic graft-versus-host disease: biological insights from preclinical and clinical studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21245483" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Effector CD4+ T cells, the cytokines they generate, and GVHD: something old and something new.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17222762" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Transplantation's greatest challenges: advances in chronic graft-versus-host disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20404486" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Rapamycin generates anti-apoptotic human Th1/Tc1 cells via autophagy for induction of xenogeneic GVHD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26265697" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : GVHD-associated, inflammasome-mediated loss of function in adoptively transferred myeloid-derived suppressor cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31533918" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Danger-associated extracellular ATP counters MDSC therapeutic efficacy in acute GVHD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36542690" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Humanβ-defensin 2 ameliorates acute GVHD by limiting ileal neutrophil infiltration and restraining T cell receptor signaling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26649819" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Interleukin-22 promotes intestinal-stem-cell-mediated epithelial regeneration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21282378" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : The Wnt agonist R-spondin1 regulates systemic graft-versus-host disease by protecting intestinal stem cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10397751" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Keratinocyte growth factor separates graft-versus-leukemia effects from graft-versus-host disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32542357" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Glucagon-like peptide 2 for intestinal stem cell and Paneth cell repair during graft-versus-host disease in mice and humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11413166" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : LPS antagonism reduces graft-versus-host disease and preserves graft-versus-leukemia activity after experimental bone marrow transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23262974" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : TLR4 inactivation protects from graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10449438" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Differential roles of IL-1 and TNF-alpha on graft-versus-host disease and graft versus leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23980097" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : The Nlrp3 inflammasome regulates acute graft-versus-host disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15090455" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Both donor and recipient NOD2/CARD15 mutations associate with transplant-related mortality and GvHD following allogeneic stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28665299" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Cytokine mediators of chronic graft-versus-host disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16522809" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Inhibition of CD4+CD25+ regulatory T-cell function by calcineurin-dependent interleukin-2 production.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23709681" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Thymic damage, impaired negative selection, and development of chronic graft-versus-host disease caused by donor CD4+ and CD8+ T cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20435882" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Stem cell mobilization with G-CSF induces type 17 differentiation and promotes scleroderma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20559327" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : FOXP3+ regulatory T cells in the human immune system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20389017" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Altered regulatory T cell homeostasis in patients with CD4+ lymphopenia following allogeneic hematopoietic stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17032915" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Donor-derived thymic-dependent T cells cause chronic graft-versus-host disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28738016" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Eomesodermin promotes the development of type 1 regulatory T (TR1) cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20807889" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Bone marrow myeloid-derived suppressor cells (MDSCs) inhibit graft-versus-host disease (GVHD) via an arginase-1-dependent mechanism that is up-regulated by interleukin-13.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29728401" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Immune regulatory cell infusion for graft-versus-host disease prevention and therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16543073" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : The development of autoantibodies after allogeneic stem cell transplantation is related with chronic graft-vs-host disease and immune recovery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22772564" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Mechanisms of fibrosis: therapeutic translation for fibrotic disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28941323" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : A critical role for donor-derived IL-22 in cutaneous chronic GVHD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25157821" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : CSF-1-dependant donor-derived macrophages mediate chronic graft-versus-host disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9864187" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : DNA typing for HLA-A and HLA-B identifies disparities between patients and unrelated donors matched by HLA-A and HLA-B serology and HLA-DRB1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7522644" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Prevention of graft-versus-host disease by peptides binding to class II major histocompatibility complex molecules.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8152486" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : A rationally designed CD4 analogue inhibits experimental allergic encephalomyelitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31690218" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Notch signalling in T cell homeostasis and differentiation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34101618" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Insights from integrating clinical and preclinical studies advance understanding of graft-versus-host disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24492144" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Metagenomic analysis of the stool microbiome in patients receiving allogeneic stem cell transplantation: loss of diversity is associated with use of systemic antibiotics and more pronounced in gastrointestinal graft-versus-host disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22718773" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Intestinal domination and the risk of bacteremia in patients undergoing allogeneic hematopoietic stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29020185" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Stool Microbiota at Neutrophil Recovery Is Predictive for Severe Acute Graft vs Host Disease After Hematopoietic Cell Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31976518" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Compositional Flux Within the Intestinal Microbiota and Risk for Bloodstream Infection With Gram-negative Bacteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32101664" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Microbiota as Predictor of Mortality in Allogeneic Hematopoietic-Cell Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24939656" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : The effects of intestinal tract bacterial diversity on mortality following allogeneic hematopoietic stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28296584" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Intestinal Microbiota and Relapse After Hematopoietic-Cell Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29674425" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Impact of gut colonization with butyrate-producing microbiota on respiratory viral infection following allo-HCT.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
